Suven Life Sciences Limited - Company Profile

Q: Who are the current directors of Suven Life Sciences Limited?

The current directors of Suven Life Sciences Limited are Santanu Mukherjee, Mohan Kumar Mallarapu, Sudharani Jasti, Venkateswarlu Jasti, Vajja Sambasiva Rao, Seyed Ehtesham Hasnain, Shrenik Soni, Ananthasai Padmaja Jasthi.

It is a pharma public limited company based in Hyderabad, Telangana, India, established in 1989.

1989 Hyderabad, Telangana, India Active

Last Updated: January 06, 2026

Access Report

About Suven Life Sciences Limited

Suven Life Sciences Limited, a active public limited company, was established on 09 March 1989 in Hyderabad, Telangana, India. Engaging in pharma contract r&d within the professional, scientific and technical sector, it holds CIN: L24110TG1989PLC009713. Registered under ROC Roc Hyderabad. it is listed on BSE: 530239 and NSE: SUVEN. It has an authorized capital of ₹50.00 Cr and a paid-up capital of ₹22.75 Cr.

Formerly known as Suven Synthesis Ltd, Suven Pharmaceuticals Pvt Ltd. It upholds a compliant status. In 2023, it reported revenue of ₹21.99 Cr and a net worth of ₹853.44 Cr. Employing 137 professional, Its leadership includes Santanu Mukherjee (Director), Sudharani Jasti (Whole-Time Director), Venkateswarlu Jasti (Managing Director). Past directors included Sambasiva Ramachandran, Hanumantha Rao Kokkonda, Santanu Mukherjee. It holds no open charges and ₹239.04 Cr settled loans. Its latest AGM occurred on 22 August 2025, with the balance sheet filed on 31 March 2025. It is based at Door No. 8-2-334, 6Th Floor, Sde Serene Chambers Road No. 5, Avenue 7, Banjara Hills, Hyderabad, Telangana, 500034.

Company Details

CIN/LLPIN
L24110TG1989PLC009713
Registration Number
009713
Incorporation Date
09 March 1989
Authorized Capital
₹50.00 Cr
Paid-Up Capital
₹22.75 Cr
ROC Code
Roc Hyderabad
Listing Status
Listed (BSE: 530239, NSE: SUVEN)
Company Status
Active

Key Metrics

Authorised Capital ₹ 50.00 Cr as on 06-01-2026
Paid Up Capital ₹ 22.75 Cr as on 06-01-2026
Company Age 36 Year, 10 Months
Last Filing with ROC 31 Mar 2025
Satisfied Charges ₹ 239.04 Cr as on 06-01-2026
Revenue Growth **** 28.13% (FY 2023)
Profit Growth **** 44.47% (FY 2023)
Ebitda **** 80.23% (FY 2023)
Net Worth 79.30% (FY 2023)
Total Assets **** 76.92% (FY 2023)

Comprehensive Company Insights

Explore comprehensive insights into Suven Life Sciences Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report

Who are the key members and board of directors at Suven Life Sciences Limited?

Current Directors

Name	Designation	Appointment Date	Status
Santanu Mukherjee	Director	15 May 2018	Current
Sudharani Jasti	Whole-Time Director	04 Jan 2013	Current
Venkateswarlu Jasti	Managing Director	04 Jan 2010	Current
Vajja Sambasiva Rao	Director	30 Jan 2024	Current
Seyed Ehtesham Hasnain	Director	30 Apr 2010	Current
Ananthasai Padmaja Jasthi	Director	14 Nov 2018	Current

Past Directors

Name	Designation	Cessation	Status
Pramod Abcsdd	Director	27 Jul 2010	Past
Pramod Abcsdd	Company Secretary	10 Jan 2020	Past
Pramod Abcsdd	Additional Director	14 Aug 2018	Past
Pramod Abcsdd	Ceo	-	Past
Pramod Abcsdd	Additional Director	04 Mar 2024	Past
Pramod Abcsdd	Additional Director	27 Jul 2010	Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Suven Life Sciences.

Suven Life Sciences Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 28.13% increase. The company also saw a substantial improvement in profitability, with a 44.47% increase in profit. The company's net worth Soared by an impressive increase of 79.3%.

Date	Amount	Transaction Name	Valuation	Lead Investors	Investors
Jul, 2021	Amount	Post-IPO - Grab	Valuation	investors	Emtek
Feb, 2021	Amount	Post-IPO - Grab	Valuation	investors	Signite Partners
Jan, 2021	Amount	Post-IPO - Grab	Valuation	investors	Hana Financial Group , GGV Capital
Feb, 2021	Amount	Post-IPO - Grab	Valuation	investors	Signite Partners

Upgrade Required

Full access to Financial is available only for users with an active Premium plan.

Key Matrics
Balance Sheet
Profit and Loss
Cash Flow
Ratios

Metrics

(FY 2023)

YOY Growth

(FY 2022)

(FY 2021)

(FY 2020)

(FY 2019)

Total Revenue

********

28.13%

*******

Revenue from Operations

*******

14.31%

*******

Total Assets

*******

76.92%

*******

Profit or Loss

*******

44.47%

*******

Net Worth

*******

79.30%

*******

EBITDA

*******

80.23%

*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Suven Life Sciences?

In 2023, Suven Life Sciences had a promoter holding of 69.56% and a public holding of 30.43%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)

Promoters: 92.83%
Public: 4.10%
Others: 3.07%

Shareholding Pattern over the Year

	FY (2024)	FY (2023)	FY (2022)	FY (2021)	FY (2020)
Promoters	92.83	94.62	94.55	94.55	94.55
Public	4.10	3.89	3.95	3.96	3.98
Others	3.07	1.49	1.50	1.49	1.47

Upgrade Required

Full access to Ownership and Shareholding Structure is available only for users with an active Premium plan.

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)

Open Charges

₹0

Satisfied Charges

₹2,390,412,500.00

Charges Breakdown by Lending Institutions

State Bank Of India : 147.51 Cr
Bank Of Bahrain And Kuwait Bsc : 36.00 Cr
Bank Of India : 22.63 Cr
State Of Bank Patiala : 20.00 Cr
Export -- Import Bank Of India : 6.00 Cr
Others : 6.90 Cr

Latest Charge Details

Date	Lender	Amount	Status
06 Dec 2012	Bank Of Bahrain And Kuwait Bsc	₹6.00 Cr	Satisfied
24 Aug 2012	Bank Of Bahrain And Kuwait Bsc	₹30.00 Cr	Satisfied
17 Feb 2011	Bank Of India	₹22.63 Cr	Satisfied
14 Jul 2010	State Of Bank Patiala	₹20.00 Cr	Satisfied
30 Aug 2007	State Bank Of India	₹25.35 Cr	Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Suven Life Sciences?

Suven Life Sciences has a workforce of 137 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date	Number of Employees
2020	78,000
2021	80,500
2022	83,200
2023	86,000
2024	89,500
2025	92,000

Upgrade Required

Full access to People is available only for users with an active Premium plan.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Suven Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Suven Life Sciences's trajectory.

Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Suven Life Sciences

Recent Activity within the Organization

Annual General Meeting

Progress on Suven Life Sciences Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records. was documented.
22 Aug 2025
Balance Sheet

The activity Suven Life Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was completed.
31 Mar 2025
Director Appointment

Progress on Vajja Sambasiva Rao was appointed as a Director was appointed as a Director on 30 Jan 2024 & has been associated with this company since 2 years 3 days . was documented.
30 Jan 2024
Charges

The activity A charge registered on 06 Dec 2012 via Charge ID 10393384 with Bank Of Bahrain And Kuwait Bsc was fully satisfied on 07 Jan 2021. was completed.
07 Jan 2021
Charges

Progress on A charge registered on 26 Feb 1990 via Charge ID 90135165 with State Bank Of India was fully satisfied on 03 Dec 2020. was documented.
03 Dec 2020
Director Appointment

Mohan Kumar Mallarapu was appointed as a CFO was appointed as a CFO on 10 Jan 2020 & has been associated with this company since 6 years 23 days . was recorded as a recent event.
10 Jan 2020

Explore recent activity and updates - View Recent Activity